Cerşit Sinan, Bayam Emrah, Gündüz Sabahattin, Özkan Mehmet
Kartal Koşuyolu Heart Training and Research Hospital, Department of Cardiology, İstanbul, Turkey. Electronic correspondence:
Kartal Koşuyolu Heart Training and Research Hospital, Department of Cardiology, İstanbul, Turkey.
J Heart Valve Dis. 2017 Sep;26(5):585-588.
Mitral annuloplasty ring thrombosis is an extremely infrequent pathology, for which no evidence-based antithrombotic management has yet been described. Herein is presented a case of heterozygous Factor V Leiden (FVL) and hyperhomocysteinemia with homozygous methylenetetrahydrofolate reductase (MTHFR) mutations that caused early thrombosis of the mitral annuloplasty ring. The clinical management and antithrombotic treatment of the patient, and the implications of hyperhomocysteinemia, are discussed. Video 1: Mobile 9-mm thrombus of mitral annuloplasty ring on two-dimensional (2D) transesophageal echocardiography. Video 2: Mitral annuloplasty ring thrombus on real time three-dimensional (RT-3D) transesophageal echocardiography. Video 3: 2D video showing the morphologic change of mitral annuloplasty ring thrombus after prolonged UFH infusion.
